Newly Added Guidance Documents

Below is a sortable list of the most recently added Guidance Documents.

You can sort alphabetically by: Category/Subject Area; Guidance Title; Guidance Type (Draft or Final) and also sort by the Date the Guidance was issued.

Newly Added Guidance Documents

Guidance Documents will be retained in this section of the page for a period of three months. The most recently added appears first and they are in the order of the date they were issued.

Procedural Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data (PDF - 138KB) Draft Guidance 12/20/18
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, updated December 2018 Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (PDF - 225KB) Final Guidance 12/19/18
Pharmaceutical Quality/Manufacturing Standards (CGMP) Data Integrity and Compliance With Current Good Manufacturing Practice Guidance for Industry (PDF - 127KB) Final Guidance 12/12/18
Drug Development Tools Biomarker Qualification: Evidentiary Framework (PDF - 346KB) Draft Guidance 12/11/18
Procedural The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers (PDF - 427KB) Draft Guidance 12/11/18
Procedural Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009 (PDF - 410KB) Final Guidance 12/11/18
Biosimilarity New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2) (PDF - 679KB) Draft Guidance 12/11/18
Biosimilars Questions and Answers on Biosimilar Development and the BPCI Act (PDF - 343KB) Final Guidance 12/11/18
Compounding/Pharmaceutical Quality/Manufacturing Standards (CGMP) Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act (PDF - 476KB) Draft Guidance 12/10/18
Clinical/Medical Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (PDF - 98KB) Draft Guidance 12/03/18
Generics / User Fees Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA (PDF - 101KB) Final Guidance 12/03/18
Clinical / Medical Nonmetastatic, Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials (PDF - 72KB) Draft Guidance 11/13/18
Drug Safety; Biostatistics Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products Guidance for Industry (PDF - 227KB) Draft Guidance 11/06/18
Clinical / Medical Hypertension: Developing Fixed-Dose Combination Drugs for Treatment Guidance for Industry (PDF - 96KB) Final Guidance 11/06/18
Clinical / Antimicrobial Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment (PDF - 507KB) Draft Guidance 11/01/18
ICH – Multidisciplinary M9 Biopharmaceutics Classification System-Based Biowaivers (PDF - 460KB) Draft Guidance 10/25/18
Procedural Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs Guidance for Industry (PDF - 357KB) Draft Guidance 10/24/18
Clinical / Medical; Pharmacology / Toxicology Testicular Toxicity: Evaluation During Drug Development Guidance for Industry (PDF - 180KB) Final Guidance 10/24/18
Advertising Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry (PDF - 161KB) Draft Guidance 10/16/18
Clinical / Medical Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment Guidance for Industry (PDF - 174KB) Draft Guidance 10/15/18
Rare Diseases Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings Guidance for Industry (PDF - 132KB) Draft Guidance 10/15/18
Clinical Pharmacology Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease; Guidance for Industry (PDF - 91KB) Final Guidance 10/15/18
Generics Assessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs Draft Guidance for Industry (PDF - 187KB) Revised Draft Guidance 10/09/18
Generics Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs Guidance for Industry (PDF - 235KB) Draft Guidance 10/09/18
Procedural Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act. (PDF - 194KB) Draft Guidance (revised final) 10/02/18
Pharmaceutical Quality/CMC Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use (PDF - 167KB) Final Guidance 10/02/18
Clinical / Medical Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs (PDF - 71KB) Final Guidance 10/02/18

Page Last Updated: 12/20/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English